NEW YORK (GenomeWeb News) — TheraGenetics has raised $6 million in a Series A round of venture capital financing, the company said Tuesday.  
 
TheraGenetics CEO Richard Kivel said the funds will help expand the company’s IP position and will speed its diagnostic development.
 
The company has developed a series of diagnostics for disorders affecting the central nervous system such as schizophrenia, Alzheimer’s disease, and mood disorders.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.